Page last updated: 2024-10-24
celecoxib and Nausea
celecoxib has been researched along with Nausea in 8 studies
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo." | 6.53 | Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016) |
| "The combination of celecoxib with docetaxel and irinotecan did not ameliorate irinotecan-induced diarrhea." | 5.11 | A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. ( Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP, 2005) |
| "To determine the upper gastrointestinal (GI) tolerability of celecoxib, naproxen, and placebo in patients with rheumatoid arthritis (RA) and osteoarthritis (OA)." | 5.09 | Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. ( Agrawal, NM; Bensen, WG; Burke, TA; Geis, GS; Makuch, RW; Maurath, CJ; Zabinski, RA; Zhao, SZ, 2000) |
| "The aim of this meta-analysis was to assess the analgesic efficacy and adverse effects of celecoxib compared to non-opioid drugs after third molar surgery." | 2.82 | Analgesic effectiveness and safety of celecoxib versus non-opioid active controls after third molar surgery: A meta-analytical evaluation. ( Alonso-Castro, ÁJ; Franco-de la Torre, L; Franco-González, MA; Isiordia-Espinoza, MA, 2022) |
| "Celecoxib 400 mg was taken orally twice daily during chemoradiation, up to 1 week before surgery, and for 6 months following surgery." | 2.82 | Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. ( Bueno, R; Choi, N; Cleary, JM; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Gaissert, HA; Jaklitsch, MT; Kulke, MH; Lynch, TP; Mamon, HJ; Mentzer, SJ; Meyerhardt, JA; Swanson, RS; Szymonifka, J; Wain, J, 2016) |
| " There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo." | 2.53 | Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016) |
Research
Studies (8)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Isiordia-Espinoza, MA | 1 |
| Franco-González, MA | 1 |
| Alonso-Castro, ÁJ | 1 |
| Franco-de la Torre, L | 1 |
| Xu, C | 1 |
| Gu, K | 1 |
| Yasen, Y | 1 |
| Hou, Y | 1 |
| Cleary, JM | 1 |
| Mamon, HJ | 1 |
| Szymonifka, J | 1 |
| Bueno, R | 1 |
| Choi, N | 1 |
| Donahue, DM | 1 |
| Fidias, PM | 1 |
| Gaissert, HA | 1 |
| Jaklitsch, MT | 1 |
| Kulke, MH | 1 |
| Lynch, TP | 1 |
| Mentzer, SJ | 1 |
| Meyerhardt, JA | 1 |
| Swanson, RS | 1 |
| Wain, J | 1 |
| Fuchs, CS | 1 |
| Enzinger, PC | 1 |
| Goldstein, JL | 1 |
| Zhao, SZ | 2 |
| Burke, TA | 2 |
| Palmer, R | 1 |
| von Allmen, H | 1 |
| Henderson, SC | 1 |
| Dy, GK | 1 |
| Mandrekar, S | 1 |
| Peethambaram, PP | 1 |
| Okuno, SH | 1 |
| Croghan, GC | 1 |
| Hanson, LJ | 1 |
| Furth, A | 1 |
| Adjei, AA | 1 |
| Csiki, I | 1 |
| Morrow, JD | 1 |
| Sandler, A | 1 |
| Shyr, Y | 1 |
| Oates, J | 1 |
| Williams, MK | 1 |
| Dang, T | 1 |
| Carbone, DP | 1 |
| Johnson, DH | 1 |
| Bensen, WG | 1 |
| Zabinski, RA | 1 |
| Makuch, RW | 1 |
| Maurath, CJ | 1 |
| Agrawal, NM | 1 |
| Geis, GS | 1 |
| Berenbaum, F | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cisplatin, CPT-11, Celecoxib (PCC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer[NCT00137852] | Phase 2 | 35 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
3 reviews available for celecoxib and Nausea
| Article | Year |
|---|---|
Analgesic effectiveness and safety of celecoxib versus non-opioid active controls after third molar surgery: A meta-analytical evaluation.
Topics: Analgesics; Celecoxib; Humans; Ibuprofen; Molar, Third; Nausea; Pain, Postoperative; Vomiting | 2022 |
Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.
Topics: Abdominal Pain; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Diarrhea; Dyspepsia; Headache; | 2016 |
[New nonsteroidal antiinflammatory drugs in rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Gastric Mucosa; Humans; L | 2002 |
Trials
4 trials available for celecoxib and Nausea
| Article | Year |
|---|---|
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2016 |
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2005 |
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Ant | 2005 |
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyg | 2000 |
Other Studies
1 other study available for celecoxib and Nausea
| Article | Year |
|---|---|
Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
Topics: Abdominal Pain; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhi | 2003 |